More than 60 percent of products do not provide adequate sun protection, contain potentially harmful chemicals.
Researchers suggest using novel therapies that act by a distinct mechanism of action to boost durable response rates in patients with treatment-resistant metastatic melanoma.
In this study, approximately one-third of patients receiving the combination of a BRAF and a MEK inhibitor following anti-PD-1 therapy required hospitalization due to an adverse event.
Female gender and ulceration were among the variables found to be predictive of a positive CLND in patients with melanoma characterized by a positive sentinel lymph node.
A retrospective study identified incidence of and treatment trends for anorectal mucosal melanoma tumors.
Merck announced that the Food and Drug Administration (FDA) has approved Keytruda(pembrolizumab) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. This marks the first approval for Keytruda in the adjuvant setting and the fourth approval for its use in skin cancers. The approval was supported by data from the phase 3,…
Eight in 10 patients with DFSP saw a clinical benefit from treatment with imatinib.
Tissue-resident memory CD8+ T cells helped suppress melanoma in an animal study.
Current treatment guidelines do not adequately cover what kind of surveillance and treatment should apply to patients with melanoma after a negative sentinel node biopsy.
The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
The discovery could provide opportunities to target resistance driven by aberrantly spliced forms of BRAF V600E.
Pembrolizumab plus dabrafenib and trametinib showed a nonsignificant improvement in PFS, but also higher rates of grade 3 to grade 5 TRAEs in advanced melanoma.
First-line nivolumab with or without ipilimumab continues to show durable survival benefits in advanced, unresectable melanoma.
T-VEC elicited substantially higher ORR in a real-world population compared with the rate that was seen in the drug maker’s phase 3 trial.
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
Treatment with ipilimumab plus nivolumab in the neoadjuvant setting resulted in high patient response rates — but it was linked to high toxicity, as well.
Future studies on checkpoint inhibition in melanoma must evaluate ways of reducing toxicity.
Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.
A computational tool appears to accurately tease out the portion of patients who might respond to checkpoint inhibitors from those who are likely to be resistant.
Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.